Funds will be used to progress lead asset ASN51, an oral small molecule OGA inhibitor, into Phase 2 clinical development for the treatment of Alzheimer’s disease Alzheimer’s disease is an area of very high unmet medical need with a lack of oral disease modifying therapies Naveed Siddiqi,…